ESMO 2026: New Targeted Therapy Improved Survival for Patients with KRAS-Mutated Lung Cancer
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Sun, 25 October 2026
What it is about
Ferdinandos SkoulidisRoche LtdEuropean Society For Medical OncologyUniversity Of Texas Md Anderson Cancer CenterTexas, United StatesMadrid, Madrid, Spain
Who published it, and when
How it spread - 1 original report
Sun, 25 October 2026
1 report- newswise.com15:30first to report
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.